Thornburg Investment Management Inc. Takes Position in Artivion, Inc. (NYSE:AORT)

Thornburg Investment Management Inc. bought a new position in shares of Artivion, Inc. (NYSE:AORT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 132,672 shares of the company's stock, valued at approximately $3,261,000. Thornburg Investment Management Inc. owned 0.31% of Artivion at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of AORT. Millennium Management LLC increased its holdings in shares of Artivion by 25.1% during the fourth quarter. Millennium Management LLC now owns 165,482 shares of the company's stock worth $4,731,000 after buying an additional 33,220 shares in the last quarter. KLP Kapitalforvaltning AS bought a new stake in Artivion during the 4th quarter worth approximately $194,000. Illinois Municipal Retirement Fund increased its holdings in Artivion by 3.1% during the 1st quarter. Illinois Municipal Retirement Fund now owns 20,519 shares of the company's stock valued at $504,000 after purchasing an additional 611 shares in the last quarter. Principal Financial Group Inc. increased its holdings in Artivion by 2.4% during the 1st quarter. Principal Financial Group Inc. now owns 206,777 shares of the company's stock valued at $5,083,000 after purchasing an additional 4,749 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its position in Artivion by 64.2% in the 4th quarter. JPMorgan Chase & Co. now owns 160,796 shares of the company's stock valued at $4,597,000 after purchasing an additional 62,893 shares during the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Needham & Company LLC restated a "buy" rating and set a $32.00 target price on shares of Artivion in a report on Tuesday, May 6th. Canaccord Genuity Group assumed coverage on shares of Artivion in a research report on Tuesday, June 17th. They issued a "buy" rating and a $35.00 price objective for the company. Citizens Jmp upgraded shares of Artivion to a "strong-buy" rating in a research report on Tuesday, May 6th. Finally, JMP Securities reissued a "market outperform" rating and set a $33.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Artivion has an average rating of "Buy" and a consensus target price of $32.40.

Artivion Trading Up 0.1%

Shares of AORT traded up $0.04 on Friday, reaching $30.95. 284,640 shares of the company's stock were exchanged, compared to its average volume of 301,105. The business has a 50 day moving average price of $30.27 and a two-hundred day moving average price of $27.90. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $32.94. The stock has a market capitalization of $1.32 billion, a P/E ratio of -61.90 and a beta of 1.64. The company has a current ratio of 5.53, a quick ratio of 3.95 and a debt-to-equity ratio of 1.08.

Artivion (NYSE:AORT - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.12 by ($0.06). The firm had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 5.49% and a positive return on equity of 3.63%. Research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Buying and Selling

In other Artivion news, SVP Marshall S. Stanton sold 26,132 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $28.44, for a total transaction of $743,194.08. Following the sale, the senior vice president directly owned 79,200 shares of the company's stock, valued at $2,252,448. The trade was a 24.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Jean F. Holloway sold 9,926 shares of the business's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $29.00, for a total value of $287,854.00. Following the transaction, the senior vice president directly owned 187,258 shares in the company, valued at $5,430,482. This trade represents a 5.03% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,954 shares of company stock valued at $2,108,525. Company insiders own 7.60% of the company's stock.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.